Bharat Biotech International Limited (BBIL) has introduced Hillchol (BBV131), a groundbreaking oral cholera vaccine (OCV) aimed at combating the global cholera crisis. This vaccine represents a significant step forward in public health, addressing a crucial shortage of cholera vaccines worldwide.
Global Cholera Challenge
Cholera remains a severe public health issue, with rising cases and fatalities since 2021. In 2023 alone, 824,479 cases and 5,900 deaths were reported across 31 countries. Despite being preventable and treatable, cholera’s global impact continues to grow, emphasizing the need for effective vaccines.
Hillchol: A Next-Generation Solution
Hillchol, developed under license from Hilleman Laboratories, is a novel, single-strain oral cholera vaccine. Administered in two doses (day 0 and day 14), it is suitable for individuals older than one year. This vaccine aims to bridge the existing gap in cholera prevention, as only one manufacturer currently supplies OCVs globally, resulting in an annual deficit of 40 million doses.
Enhanced Manufacturing Capabilities
To meet this demand, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar, capable of producing up to 200 million doses of Hillchol annually. These facilities are expected to significantly boost the global supply of cholera vaccines, providing a much-needed solution to the ongoing crisis.
Leadership’s Vision
Dr. Krishna Ella, Executive Chairman of Bharat Biotech, emphasized the importance of vaccines in controlling cholera outbreaks. He stated, “Vaccines provide the best intervention to prevent, limit, and control cholera outbreaks. Our new large-scale cGMP production facilities will significantly enhance our production and supply capabilities for this Oral Cholera Vaccine, advancing our efforts to combat cholera globally.”
Bharat Biotech’s launch of Hillchol marks a major advancement in global health efforts to combat cholera. With enhanced manufacturing capabilities and a commitment to bridging the vaccine gap, this next-generation oral cholera vaccine promises to play a crucial role in preventing the spread of cholera worldwide.
